Monoclonal gammopathy of undetermined significance is a premalignant, plasma cell disorder. Due to the potential risk of progression to multiple myeloma or a plasma cell-related disorder, it is important for GPs to recognise and manage patients in this cohort appropriately. This article aims to improve understanding, recognition and management of these patients in primary care.
Get full access to this article
View all access options for this article.
References
1.
AxelssonUBachmannRHällénJ (2009) Frequency of pathological proteins (M-components) in 6,995 sera from an adult population. Acta Medica Scandinavica179(2): 235–247. DOI: 10.1111/j.0954-6820.1966.tb05453.x.
2.
BianchiGKyleRColbyC, et al. (2010) Impact of optimal follow-up of monoclonal gammopathy of undetermined significance on early diagnosis and prevention of myeloma-related complications. Blood 116122019–2025. DOI: 10.1182/blood-2010-04-277566.
3.
BirdJBehrensJWestinJ, et al. (2009) UK Myeloma Forum (UKMF) and Nordic Myeloma Study Group (NMSG): Guidelines for the investigation of newly detected M-proteins and the management of monoclonal gammopathy of undetermined significance (MGUS). British Journal of Haematology147(1): 22–42. DOI: 10.1111/j.1365-2141.2009.07807.x.
4.
British Journal of Haematology (2003) Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: A report of the International Myeloma Working Group 121(5): 749–757. DOI: 10.1046/j.1365-2141.2003.04355.x.
5.
GoRRajkumarV (2018) How I manage monoclonal gammopathy of undetermined significance. Blood131(2): 163–173. DOI: 10.1182/blood-2017-09-807560.
6.
KyleRDurieBRajkumarS, et al. (2010) Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management. Leukemia24(6): 1121–1127. DOI: 10.1038/leu.2010.60.
RawstronAJonesRFergusonC, et al. (2007) Outreach monitoring service for patients with indolent B-cell and plasma cell disorders: A UK experience. British Journal of Haematology139(5): 845–848. DOI: 10.1111/j.1365-2141.2007.06864.x.
